Program Overview

IN-PERSON & VIRTUAL CONFERENCE
The application of immunotherapies and cellular therapies in the treatment of cancer have provided tremendous insight into the functions of the immune system. Immunotherapies for solid cancers have greatly enhanced the care of many patients, but have also caused issues in the form of immune-related adverse events, with a multitude of acute and chronic autoimmune complications for patients. Similarly, cellular therapies such as CAR-T cell therapy have significantly improved the treatment of many hematologic malignancies, but have also revealed the potential for these treatments to cause cytokine storm and other severe complications. Research and development of these treatments have taught us a great deal about immune system regulation and dysregulation in general, providing insights into the pathogenesis of autoimmune disease and even stimulating exploration of treatments like CAR-T cell therapy in lupus and PD-1 agonist treatment in rheumatoid arthritis. In this CME course, we bring together the leading national and international experts from oncology, rheumatology, and multiple other specialties to provide a comprehensive overview of the latest insights into diagnosis, management, and future areas of exploration in the realms of cancer and autoimmune disease.

Please note:  In-person registration includes light breakfast and lunch

Video Access
Following the program, all registrants will have access to lecture video recordings for ONE month.

Learning Objectives
-Describe the pathobiology and clinical uses of cellular therapy and immunotherapy in cancer
-List the acute and chronic immune-related adverse events in cancer immunotherapy   

-Describe the potential complications of cellular therapy in cancer
-Identify treatment strategies to mitigate adverse effects of cellular therapy and immunotherapy in cancer
-Understand the impact of immunotherapy and cellular therapy in patients with pre-existing autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Columbia University. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 Amedco Joint Accreditation #4008163.

Physicians (ACCME) Credit Designation Statement

Amedco LLC designates this live virtual activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 



Physician Assistants

PAs may claim a maximum of 7.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 7.25 hours.